Immunovia Past Earnings Performance

Past criteria checks 0/6

Immunovia's earnings have been declining at an average annual rate of -14.6%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 72.8% per year.

Key information

-14.6%

Earnings growth rate

-0.5%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate72.8%
Return on equity-333.3%
Net Margin-20,353.0%
Next Earnings Update25 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Immunovia makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0G8X Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-129850
30 Jun 241-1161010
31 Mar 241-2611280
31 Dec 232-3091480
30 Sep 232-3281730
30 Jun 232-3121710
31 Mar 231-1761650
31 Dec 221-1681630
30 Sep 221-1481620
30 Jun 221-1611580
31 Mar 221-1771650
31 Dec 211-1561620
30 Sep 211-1551650
30 Jun 210-1571750
31 Mar 210-1421610
31 Dec 200-1461650
30 Sep 200-1332130
30 Jun 200-1201840
31 Mar 200-1161620
31 Dec 190-1151330
30 Sep 19-19-108520
30 Jun 19-13-99510
31 Mar 19-6-96480
31 Dec 180-87450
30 Sep 1829-76460
30 Jun 1826-70380
31 Mar 1825-55340
31 Dec 1724-45310
30 Sep 1723-35240
30 Jun 1724-28230
31 Mar 1725-20190
31 Dec 1624-15160
30 Sep 1622-11120
30 Jun 1622-9110
31 Mar 1619-890
31 Dec 1517-770
30 Sep 1512-950
30 Jun 157-1040
31 Mar 154-930
31 Dec 140-920
31 Dec 131-210

Quality Earnings: 0G8X is currently unprofitable.

Growing Profit Margin: 0G8X is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0G8X is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare 0G8X's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0G8X is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (39.9%).


Return on Equity

High ROE: 0G8X has a negative Return on Equity (-333.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 15:54
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunovia AB (publ) is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lars HevrengDanske Bank
Juan Pedro Rodríguez SerrateEdison Investment Research
Alexandru CogutKempen & Co. NV